KLRC4-KLRK1/CD314 Drug Discovery Landscape & Assay Solutions
Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLRC4-KLRK1/CD314 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLRC4-KLRK1/CD314 ECD-Fc / Monomer Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View KLRC4-KLRK1/CD314 Products |
| Gene Delivery | KLRC4-KLRK1/CD314 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native conformation and signaling. |
View KLRC4-KLRK1/CD314 Products |
| Benchmark Ab | Anti-KLRC4-KLRK1/CD314 (Sequence of clinical benchmark NNC0142) Recombinant positive control for blocking and binding assays. |
View KLRC4-KLRK1/CD314 Products |
| Validator | KLRC4-KLRK1/CD314 siRNA Set For target knockdown validation in primary NK and T cells. |
View KLRC4-KLRK1/CD314 Products |
| Related Target A | MICA Stress-induced NKG2D ligand; critical for ligand-blocking and shedding escape assays. |
View MICA Products |
| Related Target B | CD16a (FCGR3A) Co-activating receptor on NK cells; essential for multi-specific NK cell engager (NKCE) screening. |
View CD16a Products |
| Related Target C | NKG2A (KLRC1) Inhibitory counterpart; critical for specificity screening to avoid off-target toxicity. |
View NKG2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native homodimeric conformation and DAP10 adaptor association | Lentiviral transduction system for robust CD314-DAP10 co-expression in stable indicator cell lines. |
| Cross-species reactivity screening (Human vs. Cynomolgus/Mouse) | Orthologous recombinant proteins verified by mass spectrometry and HPLC with >95% purity. |
| High-concentration assay stability for subcutaneous formulation | Formulation-ready, low-aggregation recombinant proteins with endotoxin strictly controlled (<1.0 EU/μg). |
| Ligand-shedding interference by soluble MICA/B | Recombinant soluble MICA/B proteins available to evaluate antibody resistance to ligand decoy escape. |
Live KLRC4-KLRK1/CD314 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of KLRC4-KLRK1/CD314 (NKG2D) represents a highly dynamic frontier bridging auto-inflammatory diseases and oncology. As a master activating receptor on NK cells, CD8+ T cells, and gammadelta T cells, CD314 modulation requires a bifurcated drug design strategy. In autoimmune conditions such as Celiac disease and Crohn's disease, the clinical focus centers on blocking antibodies to suppress aberrant intraepithelial lymphocyte activation. Conversely, in oncology, the field is shifting rapidly toward multi-specific NK cell engagers (NKCEs) and CAR-NK/T therapies that harness NKG2D activation to eradicate solid and hematological malignancies.
As next-generation multi-specifics enter clinical phases, achieving precise affinity tuning and avoiding off-target interactions with highly homologous receptors (such as NKG2A or NKG2C) have emerged as primary developmental hurdles. Addressing these challenges requires structurally validated antigens and robust cell-based signaling assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Blocking) | Novo Nordisk, Amgen | Celiac Disease, Crohn's Disease, Rheumatoid Arthritis | Ligand-blocking assays and internalization assays (Requires high-purity CD314 ECD-Fc and benchmark NNC0142). |
| NK Cell Engagers (NKCE) | Sanofi, Innate Pharma, DragonFly Therapeutics | Solid Tumors, AML, Colorectal Cancer | Multi-specific binding affinity profiling (Requires CD314, CD16a, and tumor-associated antigens in monomeric/dimeric states). |
| CAR-T / CAR-NK (NKG2D-based) | Celyad Oncology, NKarta Therapeutics | Myelodysplastic Syndromes, Acute Myeloid Leukemia | Target cell line generation and functional cytolytic validation (Requires high-titer Lentivirus for stable CD314/ligand expression). |
===PART_II_START===
全球研发格局 (Global R&D Landscape)
KLRC4-KLRK1（常被称为 NKG2D 或 CD314）是天然杀伤（NK）细胞和 CD8+ T 细胞上最具代表性的活化性受体之一。该靶点在免疫监视、肿瘤清除以及自身免疫性疾病的病理过程中发挥着“双刃剑”的作用。
-
自免领域的阻断性抗体： 在乳糜泻（Celiac Disease）、克罗恩病（Crohn's Disease）等自免疾病中，NKG2D 与其配体（如 MICA/B）的过度结合会导致上皮内淋巴细胞（IELs）异常活化，进而破坏组织。目前，诺和诺德（Novo Nordisk）的 NNC0142（已进入 II 期临床）和安进（Amgen）等巨头在此赛道展开竞争，主要通过单抗阻断 NKG2D-配体轴来缓解炎症。
-
肿瘤领域的 NK 细胞接合器（NKCE）： 在肿瘤免疫（IO）领域，针对 CD314 的开发已从传统的单抗激活转向多特异性抗体。赛诺菲（Sanofi）、Innate Pharma 和 Dragonfly Therapeutics 等企业正在大力开发三特异性或四特异性 NKCE（例如：TAA x CD16a x CD314 x IL-15）。这些分子通过同时结合肿瘤相关抗原（TAA）、CD16a 和 CD314，实现对 NK 细胞的超强激活与精准靶向。
-
CAR-NK/T 细胞疗法： 利用 NKG2D 的胞外域（ECD）作为嵌合抗原受体（CAR）的抗原结合域（即 NKG2D-CAR），由于 NKG2D 天然能识别多种肿瘤细胞表面上调的应激配体（MICA/B, ULBPs），因此这种设计具备“广谱抗肿瘤”的潜力。代表企业包括 Celyad Oncology（CYAD-01/02）和 Nkart Therapeutics。
前瞻性市场预测 (Future Forecast)
-
NK 细胞接合器（NKCE）的爆发： 未来 3-5 年内，基于 CD314 的多特异性抗体将逐步进入后期临床。相比于 T 细胞接合器（TCE）易引发的细胞因子释放综合征（CRS），NKCE 展现出更高的安全窗。
-
配体脱落（Shedding）介导的耐药机制研究： 肿瘤细胞会通过蛋白酶剪切（如 ADAM10/17）使表面的 MICA/B 脱落，形成可溶性 sMICA/sMICB。这些游离配体作为“诱饵”结合并下调 NK 细胞表面的 CD314，导致免疫逃逸。因此，筛选对 sMICA/B 具有耐受性、或能特异性阻断脱落过程的抗体，将是下一代 CD314 靶向药物的核心研发方向。
分子差异化需求与 Assay 策略 (Molecular Differentiation & Assay Strategy)
要在 CD314 赛道开发出 Best-in-Class（同类最佳）的药物，必须在分子设计上进行精细的差异化考量。以下是核心分子属性要求及对应的 Assay 筛药策略：
1. 亲和力平衡（Affinity Tuning）
- 差异化需求：
- 自免阻断单抗： 需要极高的亲和力（pM 级别），以实现对内源性多重配体（MICA, MICB, ULBP1-6）的竞争性抑制。
- 肿瘤 NKCE： 亲和力并非越高越好。过高的 CD314 亲和力会导致药物在体循环中被外周 NK 细胞大量“汇聚”（Sink Effect），降低肿瘤局部富集度，并可能引发全身性非特异性激活。因此，NKCE 通常需要中等亲和力（10-100 nM），